British Columbia’s Ministry of Health Uses CADTH Work to Educate on Anticoagulants

Many Canadian jurisdictions are facing decisions about new oral anticoagulants for stroke prevention in patients with atrial fibrillation (the most common type of irregular heartbeat). Although the new drugs are as effective as standard therapy, they are more expensive and little is known about their long-term safety. CADTH’s review led to a recommendation that these drugs be considered second-line options.

The British Columbia Ministry of Health recently made a listing decision for one of these new drugs. In addition to evidence-based drug coverage, the Ministry is providing British Columbians with the information they need. Information pamphlets for patients and prescribers explain important issues and options.